- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2024 Financial Results | 147 | GlobeNewswire (Europe) | BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the third quarter ended September 30, 2024, and provided an... ► Artikel lesen | |
| 07.11. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08. | Ikena Oncology GAAP EPS of -$0.28 | 2 | Seeking Alpha | ||
| 08.08. | Ikena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial Results | 125 | GlobeNewswire (Europe) | BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update... ► Artikel lesen | |
| 12.07. | Ikena Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.05. | Pre-market Movers: Cheche Group, AERWINS Technologies, Siyata Mobile, Surmodics, Ikena Oncology | 551 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheche Group Inc. (CCG) is up over 58% at $2.11.
Siyata... ► Artikel lesen | |
| 29.05. | Ikena Oncology, Inc. Announces Strategic Update | 198 | GlobeNewswire (Europe) | Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring... ► Artikel lesen | |
| IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 13.05. | Ikena Oncology, Inc.: Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update | 223 | GlobeNewswire (Europe) | Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and... ► Artikel lesen | |
| 12.03. | Ikena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results | 283 | GlobeNewswire (Europe) | IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in... ► Artikel lesen | |
| 21.02. | Ikena Oncology, Inc.: Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer | 220 | GlobeNewswire (Europe) | Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy... ► Artikel lesen | |
| 18.01. | Ikena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate Updates | 399 | GlobeNewswire (Europe) | IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -4,23 % | WARBURG RESEARCH stuft Evotec auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Warburg Research hat die Einstufung für Evotec auf "Buy" mit einem Kursziel von 14 Euro belassen. Die Aktie des Wirkstoffforschers gehöre zu den "Best Ideas 2025" des Analysehauses... ► Artikel lesen | |
| EPIGENOMICS | 1,500 | +1,35 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOGEN | 142,50 | +0,60 % | Biogen Aktie: Skepsis wächst merklich | Die Aktie des US-Biotech-Unternehmens Biogen verzeichnet zum Ende des Jahres 2024 weitere Verluste. Der Kurs fiel am 14. Dezember auf 150,03 USD, was einem Tagesrückgang von 3,41 Prozent entspricht.... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,731 | +0,41 % | Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds | ||
| MAINZ BIOMED | 5,695 | -100,00 % | Mainz BioMed NV: Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering | BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 36,960 | +0,14 % | What's Going On With Viking Therapeutics Stock On Wednesday? | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,351 | -3,84 % | Defence Therapeutics Inc.: Defence Provides Update on Delivery of AGSM Proxy Materials | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GALAPAGOS NV | 25,520 | 0,00 % | Galapagos NV: Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma | Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96%... ► Artikel lesen | |
| CENTOGENE | 0,100 | +11,11 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 1,260 | +4,13 % | Affimed stock plunges 23% on AFM24 study update | ||
| GINKGO BIOWORKS | 9,150 | +7,65 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| CELLECTAR BIOSCIENCES | 0,246 | +1,65 % | Cellectar Biosci-Aktie fällt auf 52-Wochen-Tief von 0,27 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 6,215 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report |
Das Unternehmen IKENA ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKENA ONCOLOGY INC finden Sie auf Wallstreet Online.
